CN100457781C - 抗癌抗体 - Google Patents

抗癌抗体 Download PDF

Info

Publication number
CN100457781C
CN100457781C CNB028073177A CN02807317A CN100457781C CN 100457781 C CN100457781 C CN 100457781C CN B028073177 A CNB028073177 A CN B028073177A CN 02807317 A CN02807317 A CN 02807317A CN 100457781 C CN100457781 C CN 100457781C
Authority
CN
China
Prior art keywords
cancer
cripto
mab
cells
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028073177A
Other languages
English (en)
Chinese (zh)
Other versions
CN1639194A (zh
Inventor
伊恩·法奎尔·坎贝尔·麦肯奇
邢培祥
胡秀凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnett Institute For Medical Research And Public Health Ltd
Original Assignee
Burnet Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnet Institute filed Critical Burnet Institute
Publication of CN1639194A publication Critical patent/CN1639194A/zh
Application granted granted Critical
Publication of CN100457781C publication Critical patent/CN100457781C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028073177A 2001-03-26 2002-03-26 抗癌抗体 Expired - Fee Related CN100457781C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
AUPR3958 2001-03-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101103851A Division CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体

Publications (2)

Publication Number Publication Date
CN1639194A CN1639194A (zh) 2005-07-13
CN100457781C true CN100457781C (zh) 2009-02-04

Family

ID=3827964

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028073177A Expired - Fee Related CN100457781C (zh) 2001-03-26 2002-03-26 抗癌抗体
CNA2008101103851A Pending CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008101103851A Pending CN101310770A (zh) 2001-03-26 2002-03-26 抗癌抗体

Country Status (9)

Country Link
US (1) US7318924B2 (cg-RX-API-DMAC10.html)
EP (1) EP1383801A4 (cg-RX-API-DMAC10.html)
JP (2) JP4854912B2 (cg-RX-API-DMAC10.html)
KR (1) KR100909290B1 (cg-RX-API-DMAC10.html)
CN (2) CN100457781C (cg-RX-API-DMAC10.html)
AU (3) AUPR395801A0 (cg-RX-API-DMAC10.html)
CA (1) CA2442318A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ528624A (cg-RX-API-DMAC10.html)
WO (1) WO2002077033A1 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
CZ20033208A3 (en) 2001-04-26 2004-03-17 Biogen, Inc. Cripto blocking antibodies and uses thereof
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP2006515985A (ja) * 2002-10-23 2006-06-15 エクセリクシス， インク． 分枝形態形成のモディファイヤーとしてのｍｂｍ及び使用方法
WO2004090158A1 (ja) * 2003-04-03 2004-10-21 Oncorex, Inc. 医薬品
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
AU2004274433B2 (en) * 2003-09-15 2010-08-12 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
JP5021309B2 (ja) 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
CA2593212A1 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
WO2007061657A2 (en) * 2005-11-14 2007-05-31 The Brigham & Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
AU2008260445A1 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
CN102272157B (zh) * 2008-11-07 2015-11-25 研究发展基金会 用于抑制cripto/grp78复合物形成和信号的组合物和方法
WO2012105219A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 抗体療法の効果増強剤
SG194567A1 (en) 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
AU2014372833B2 (en) 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
AU2016250900B2 (en) * 2015-04-20 2022-03-17 GlyTherix Ltd. Therapeutic antibodies and uses thereof
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
MX2017017138A (es) 2015-06-23 2018-04-30 Bayer Pharma AG Conjugados homogeneos especificos de sitio con inhibidores de ksp.
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体
CN122081235B (zh) * 2026-04-27 2026-08-07 浙江大学 一种诱导b-cd4+t细胞交互的冻干肿瘤组织、其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1332745A (zh) * 1999-03-11 2002-01-23 阿登尼亚投资有限公司 治疗癌症的新化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
BR9710811A (pt) 1996-05-22 1999-08-17 Novopharm Biotech Inc Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
NZ525380A (en) 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
CZ20033208A3 (en) 2001-04-26 2004-03-17 Biogen, Inc. Cripto blocking antibodies and uses thereof
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1332745A (zh) * 1999-03-11 2002-01-23 阿登尼亚投资有限公司 治疗癌症的新化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cooperative inhibiton of renal cancer growth byanti-epidermal growth factor receptor antibody and proteinkinase A antisense oligonucleotide. Fortunato Ciardiello et al.Journal of the National Cancer Institute,Vol.90 No.14. 1998 *
Inhibition of Cripto expression and tumorigenicity inhumancolon cancer cells by antisense RNAandoligodeoxynucleotides. Fortunato Ciardiello et al.Oncogene,Vol.9. 1994 *

Also Published As

Publication number Publication date
KR100909290B1 (ko) 2009-07-24
EP1383801A1 (en) 2004-01-28
CA2442318A1 (en) 2002-10-03
NZ528624A (en) 2006-03-31
AUPR395801A0 (en) 2001-04-26
CN101310770A (zh) 2008-11-26
CN1639194A (zh) 2005-07-13
KR20040010613A (ko) 2004-01-31
JP4854912B2 (ja) 2012-01-18
WO2002077033A1 (en) 2002-10-03
AU2007201587A1 (en) 2007-05-03
JP2009024014A (ja) 2009-02-05
US20040176576A1 (en) 2004-09-09
US7318924B2 (en) 2008-01-15
JP2004534741A (ja) 2004-11-18
AU2002240719B2 (en) 2007-01-11
EP1383801A4 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
JP4854912B2 (ja) 癌に対する抗体
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
AU2002240719A1 (en) Antibodies against cancer
KR102134088B1 (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN101155830B (zh) 结合epha2的抗体及其使用方法
CN110869394A (zh) 工程改造的抗体化合物及其缀合物
CN110382532B (zh) 抗g-csf抗体及其用途
JP2005508839A (ja) ペプチドおよびｍｕｃ１タンパク質に対する抗体
WO2022048521A1 (zh) 抗c-Met抗体药物偶联物及其应用
CN111848805A (zh) 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
KR20010101446A (ko) 항암 예방접종용 항체의 용도
WO2022029591A1 (en) Treatment with site specific her2 antibody-drug conjugates
BR112019020507A2 (pt) agente de alvejamento de erbb-2 e um anticorpo bispecífico com locais de ligação de antígenos que ligam um epítopo em uma parte extracelular de erbb-2 e erbb-3 para tratamento de um indivíduo com um tumor positivo erbb-2, erbb-2 / erbb-3
US20230061858A1 (en) Treatment with site specific her2 antibody-drug conjugates
CN115884794A (zh) 抗her2抗体药物缀合物与her二聚化抑制剂的组合
ES2348161T3 (es) Métodos para dañar células usando funciones efectoras de anticuerpos anti-gfra1.
US20100119514A1 (en) Antibodies Against Cancer
CN121627886A (zh) 一种特异性结合催乳素受体prlr的小鼠单克隆抗体及其应用
CN121824757A (zh) 一种能够结合催乳素受体prlr的抗体及其用途
CN121824758A (zh) 一种具有人猴交叉反应性的prlr单克隆抗体及其用途
CN121673408A (zh) 一种特异性结合prlr的小鼠单克隆抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH +

Free format text: FORMER OWNER: AUSTIN RES INST

Effective date: 20120723

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120723

Address after: Vitoria Australia

Patentee after: Macfarlane Burnett Institute for medical research and Public Health Limited

Address before: Vitoria Australia

Patentee before: Austin Res Inst

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090204

Termination date: 20130326